Classical swine fever (CSF) is a highly contagious viral disease of pigs that has a tremendous socioeconomic impact. Vaccines are available for disease control. However, most industrialized countries are implementing stamping-out strategies to eliminate the disease and avoid trade restrictions. These restrictions can be avoided through the use of marker vaccines such as CP7_E2alf. Marker vaccines have to be accompanied by reliable and robust discriminatory assays. In this context, a multiplex microsphere immunoassay for serological differentiation of infected from vaccinated animals (DIVA) was developed to distinguish CSF virus (CSFV)-infected animals from CP7_E2alf-vaccinated animals. To this end, three viral proteins, namely, CSFV E2, CSFV E rns , and bovine viral diarrhea virus (BVDV) E2, were produced in insect cells using a baculovirus expression system; they were used as antigens in a microsphere immunoassay, which was further evaluated by testing a large panel of pig sera and compared to a wellcharacterized commercial CSFV E2 antibody enzyme-linked immunosorbent assays (ELISAs) and a test version of an improved CSFV E rns antibody ELISA. Under a cutoff median fluorescence intensity value of 5,522, the multiplex microsphere immunoassay had a sensitivity of 98.5% and a specificity of 98.9% for the detection of antibodies against CSFV E2. The microsphere immunoassay and the CSFV E rns ELISA gave the same results for 155 out of 187 samples (82.8%) for the presence of CSFV E rns antibodies. This novel multiplex immunoassay is a valuable tool for measuring and differentiating immune responses to vaccination and/or infection in animals.
C
lassical swine fever (CSF) is a highly contagious and economically important viral disease of pigs and is notifiable to the World Organization for Animal Health (OIE). The causative agent, classical swine fever virus (CSFV), is a member of the Pestivirus genus within the Flaviviridae family. The other three members, namely, bovine viral diarrhea virus 1 (BVDV-1), bovine viral diarrhea virus 2 (BVDV-2), and border disease virus (BDV), can also infect domestic pigs and wild boar and cross-react with antibodies against CSFV, which might interfere with the serological diagnosis of CSF. The virus has a single-stranded positive-sense RNA genome of approximately 12.3 kb, which encodes a single polyprotein that is processed into four structural proteins, C, E rns , E1, and E2, and eight nonstructural proteins, N pro , p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B (1) . E rns is heavily glycosylated and forms disulfide-linked homodimers (2, 3) . Glycosylation and disulfide linkage are also important for E1 and E2. Glycoprotein E2 is involved in virus attachment and entry into target cells (4) and has been a target for the development of subunit vaccines (5) (6) (7) (8) . Both E rns and E2 provide protective immunity by inducing neutralizing antibodies in the host (9) (10) (11) .
According to OIE animal health information (available in the World Animal Health Information Database), CSF has been confirmed in 21 countries since 2010. Within the European Union (EU), Council Directive 2001/89/EC has laid down community measures for the control of CSF within the EU, where the use of vaccines may be authorized only in emergencies. However, the use of conventional live attenuated vaccines in domestic pigs may result in restrictions in trading live pigs or pig products due to the fact that the vaccinated pigs cannot be serologically distinguished from those infected naturally with CSFV. In addition, the increasing number of wild boar in EU member states may pose a challenge to the control and eradication of the disease in wild boar populations. All of these factors emphasize the need for novel marker vaccines, which allow not only for differentiation of infected from vaccinated animals (DIVA) but also for oral vaccination of wild boar.
Several vaccines have been developed employing different approaches (12) . Within the EU project "Epidemiology and control of classical swine fever (CSF) in wild boar and potential use of a newly developed live marker vaccine" (grant no. 501599), the marker vaccine candidate CP7_E2alf was initially tested. It is based on the backbone of the BVDV CP7 strain with the exchange of the E2 gene of CSFV strain Alfort/187 (6), which enables the differentiation of pigs infected with wild-type CSFV from those vaccinated by testing antibodies against CSFV E rns and E2. This chimeric vaccine candidate was further evaluated within the subsequent EU project "Improve tools and strategies for the prevention and control of classical swine fever" (grant no. 227003). This vaccine candidate provides early onset of protection against lethal challenge after intramuscular and oral immunization (13) and is safe for target and nontarget species (14) . Efficacy has been shown in several trials (15) (16) (17) (18) (19) , and licensing is under way. Besides efficacy and safety issues, marker vaccines have to be accompanied by reliable discriminatory assays (20) . In the case of CP7_E2alf or similar vaccines, serological DIVA can be achieved by CSFV E rns and E2 enzyme-linked immunosorbent assays (ELISAs). While several fully validated CSFV E2 ELISAs are commercially available on the market from different suppliers, only the PrioCHECK CSFV E rns ELISA was found suitable for E rns -based marker serology. An improved version of this test was temporarily available for evaluation within the consortium, but further improvements are needed in terms of sensitivity, specificity, robustness, and reproducibility (15) . Furthermore, testing the same sera with two different ELISA protocols would clearly increase hands-on time and labor intensity. In contrast, the xMAP technology (Luminex Corp., Austin, TX) allows the simultaneous detection of multiple targets, such as antibodies, in the same sample. The objective of this study was to develop a multiplex microsphere immunoassay for differentiating pigs infected with wild-type CSFV and those vaccinated with the marker vaccine candidate CP7_E2alf.
MATERIALS AND METHODS
Serum samples. A total of 365 serum samples were analyzed in this study (Table 1) . These included 33 samples from a German reference panel for ELISA batch release, 8 of which were from pigs infected with non-CSFV pestiviruses (BVDV/BDV), and 186 samples collected from different CP7_E2alf (no C-strain) vaccination/challenge studies at the FriedrichLoeffler Institut (FLI), Greifswald-Insel Riems, Germany. All the German samples had been tested for CSFV E2 antibodies and some (187 samples) for CSFV E rns antibodies (15, 18) . Sixty-six CSFV E2-positive samples were derived from experimental infections of pigs with different CSFV genotypes at the EU and OIE Reference Laboratory for CSF (TiHo), Hannover, Germany, and 80 CSFV E2-negative samples were from the National Veterinary Institute (SVA), Uppsala, Sweden. CSFV E2 antibodies were tested using an IDEXX HerdCheck CSFV Ab ELISA (IDEXX Laboratories, Shiphol-Rijk, The Netherlands), and CSFV E rns antibodies were tested using a PrioCHECK E rns ELISA (Prionics Lelystad BV, Lelystad, The Netherlands).
PCR amplification and cloning. Two microliters of plasmids containing CSFV E2, CSFV E rns , or BVDV E rns was used for amplification of the target gene regions in a 25-l reaction volume, including 12.5 l of water, 2.5 l of 10ϫ buffer, 2 l of 2.5 mM deoxynucleoside triphosphate (dNTP) mix, 2.5 l of 10 M each primer, and 1.25 U PfuUltra DNA polymerase (Agilent Technologies, Inc., Santa Clara, CA). The primers are listed in Table 2 . The fragment was excised from the gel, purified using the PCR cleanup system (Promega Co., Madison, WI), and cloned into pFast Bac/HBM TOPO vector (Invitrogen, Carlsbad, CA). The positive plasmids, designated pFastBac/HBM-CSFVE rns , pFastBac/HBM-BVDVE rns , and pFastBac/HBM-CSFVE2, were verified by DNA sequencing.
Expression of CSFV E2, CSFV E rns , and BVDV E rns using a baculovirus expression system. The plasmids were transformed into MAX efficiency DH10Bac-competent Escherichia coli cells (Invitrogen, Carlsbad, CA) to generate recombinant bacmids, which were further verified based on the phenotypic characteristics and analytical PCR according to the manufacturer's instructions. One microgram of bacmid DNA was transfected into Spodoptera frugiperda (sf9) cells using 6 l of Cellfectin II reagent (Invitrogen). The recombinant viruses were harvested after 96 h, and the virus titers were determined by a BacPAK baculovirus rapid titer kit (Clontech Laboratories, Mountain View, CA) as per the manufacturer's instructions. The protein expression was optimized by infecting the cells at a density of 2 ϫ 10 6 with multiplicity of infection (MOI) values of 1 and 2. Twenty-four hours postinfection, 0.5% fetal bovine serum (FBS) was added, and the cells were collected at 48, 72, and 96 h postinfection and centrifuged at 800 ϫ g for 5 min. Pellets were washed with 1 ml phosphate-buffered saline (PBS) and, if not used immediately, stored at Ϫ20°C. To analyze the proteins, 75 l of lysis buffer (200 mM Tris, 20% glycerol, 5 mM EDTA, 4% SDS, 50 mM dithiothreitol, 6 units of Benzonase) was added to the cell pellet and incubated at 4°C for 30 min. The pellet and supernatant were analyzed by SDS-PAGE and Western blot 
TABLE 2 Primers and nucleotide sequences Primer
Nucleotide sequence
analysis using an anti-His monoclonal antibody (Sigma, St. Louis, MO) and sera positive for CSFV E2, CSFV E rns , or BVDV E rns . Affinity purification of recombinant proteins. One milliliter of cell lysis buffer (25 mM HEPES [pH 7.4], 100 mM NaCl, 1% Triton X-100, 1ϫ protease inhibitor) was added to 1.2 ϫ 10 7 cells and incubated on ice for 45 min. The cells were sheared by brief sonication, and soluble proteins were recovered in the supernatant following ultracentrifugation at 18,000 ϫ g for 30 min at 4°C. A HisTrap chelating HP column (GE Healthcare, Uppsala, Sweden) was equilibrated with 10 column volumes of buffer A (50 mM HEPES [pH 7.4], 500 mM NaCl, 20 mM imidazole). After loading the sample, the column was washed with 10 volumes of buffer B (50 mM HEPES [pH 7.4], 400 mM NaCl, 30 mM imidazole). The proteins were eluted from the column with 100, 300, or 500 mM imidazole. The elution fractions were concentrated with a 10-kDa molecular mass cutoff Amicon Ultra-4 centrifugal filter device (Millipore Ireland B.V., County Cork, Ireland).
Microsphere immunoassay. Coupling of the recombinant proteins (CSFV E2, CSFV E rns , BVDV E rns ) to carboxylated microspheres (Luminex Corp., Austin, TX) was mediated by 1-ethyl-3-3-dimethylaminopropyl carbodiimide (Pierce, Rockford, IL), as previously described (21) . The optimal amount of protein, dilution of serum, and blocking solutions were determined experimentally. The same amounts of secondary antibody and conjugate were used as described previously (21) . The coupled microspheres were resuspended in 500 l of PBS-TBN (PBS, 0.1% bovine serum albumin [BSA], 0.02% Tween 20, 0.05% azide [pH 7.4]) and stored at 4°C in darkness. The coupling reaction was confirmed by testing positive sera.
The immunoassay was performed in 96-well plates. The coupled microspheres were resuspended in 4-fold-diluted PBS with 1% BSA, and 50 l of microspheres was transferred to each well of the plate. Fifty microliters of 4-fold-diluted PBS with 1% BSA and 50 l of sera were added to the respective wells and incubated at 37°C for 30 min on a plate shaker at 300 rpm. The microspheres were washed twice with PBS and separated by a microsphere magnet in a HydroFlex microplate washer (Tecan Group Ltd., Männedorf, Switzerland). Thereafter, 50 l of 2-g/ml biotinylated anti-swine IgG (Jackson ImmunoResearch, West Grove, PA) in the 4-fold-diluted PBS with 1% BSA was added to each well and incubated for another 30 min at 300 rpm. Following the same washing step as before, 50 l of 10-g/ml streptavidin-R-phycoerythrin conjugate (ProZyme, Inc., Hayward, CA) in PBS with 1% BSA was added to each well and incubated at 37°C for 30 min on a plate shaker at 300 rpm. After two washes, the microspheres were resuspended in 100 l of the 4-fold-diluted PBS with 1% BSA and analyzed by a Luminex 200 analyzer. Median fluorescence intensity (MFI) values were calculated based on the measurement of 100 beads per sample. Receiver operating characteristic (ROC) analysis of the microsphere immunoassay and ELISA were performed using MedCalc software (MedCalc Software, Mariakerke, Belgium) to determine the cutoff value of the microsphere immunoassay.
RESULTS
Expression and purification of recombinant proteins. Three viral proteins were produced in sf9 cells using a baculovirus expression system. The recombinant proteins contained a 6ϫHis tag at the C terminus for affinity purification. The expression of the recombinant proteins was driven by a baculovirus-specific strong promoter of Autographa californica multiple nuclear polyhedrosis virus (AcMNPV). Two CSFV proteins, E2 and E rns , were found to have high yields when sf9 cells were infected with an MOI of 2, and proteins were harvested at 96 h posttransfection. Following lysis of the cells, the two proteins were readily detected by Western blot analysis using an anti-His monoclonal antibody (Fig. 1) . While E2 protein was present both in soluble format and in association with cell membranes in the pellet after centrifugation, the E rns protein was mostly expressed in insoluble form or associated with cell membranes. The molecular mass of the E2 protein was about 55 kDa and that of the E rns protein was 35 kDa, indicating that neither of the two proteins was fully glycosylated. The two proteins reacted well with positive serum in a Western blot analysis, indicating that they retained their antigenicity. The two proteins were purified using nickel (Ni 2ϩ ) affinity chromatography, and the purified proteins were verified by Western blot analysis. Similar to CSFV E rns expression, the BVDV E rns protein was found mainly in insoluble form when cells were infected with an MOI of 1 and harvested at 72 h posttransfection. The molecular mass of the BVDV E rns protein was less than that of CSFV E rns , indicating that it was not fully glycosylated.
Optimization of the microsphere immunoassay. To set up an indirect multiplex immunoassay, each set of microspheres was coupled with one of the viral antigens, namely, CSFV E2, CSFV E rns , or BVDV E rns . The amount of each antigen was determined by comparing the MFI values of a range of antigens coupled to 1.2 million microspheres. It was found that the optimal amount was 20 g for CSFV E2, 120 g for CSFV E rns , and 20 g for BVDV E rns , which gave higher MFI values for the positive sera and lower MFI values for negative sera (see Fig. S1 in the supplemental material).
To investigate the possible effects of salt concentration on the specific binding between antibodies and antigens, five different concentrations (0, 100, 200, 300, and 400 mM) of NaCl solution were added to the CSFV E rns immunoassay, which had showed initially some degree of cross-reactivity with antibodies against BVDV E rns . With the increasing salt concentrations, MFI values for the specific binding of CSFV E rns antigen to CSFV-positive sera decreased by 28% and nonspecific binding to the CP7_E2alf-positive serum increased by 38% (see Fig. S2 in the supplemental material). This suggests that the lower the salt concentration was, the higher the specific binding between CSFV E rns antigen and antibodies became. To further reduce the salt concentration, 4-fold-diluted PBS was used in the multiplex immunoassay. Finally, a 500-fold dilution of serum was found to be optimal for testing all three antigens.
Evaluation of the multiplex immunoassay for the detection of CSFV E2 and E rns antibodies. To evaluate the sensitivity and specificity for E2 antibody detection, a total of 365 samples were tested by the multiplex immunoassay, and the results were compared to those of the ELISAs. Based on the ROC analysis, a cutoff MFI value of Ͼ5,522 was chosen for the evaluation of the diagnostic sensitivity and specificity for E2 antibody detection. Out of the 365 samples, 360 samples were correctly diagnosed, resulting in a sensitivity of 98.5% and a specificity of 98.9%. The 95% confidence intervals (CI) were 96.3 to 99.6% for the sensitivity and 94 to 100% for the specificity. The area under the ROC curve (AUC) was 0.999 (P Ͻ 0.0001). The 8 BVDV/BDV serum samples gave negative results by the immunoassay. Four false-negative serum samples, which had positive ELISA results, were taken from vaccinated pigs at 1 and 3 months postvaccination and from vaccinated/challenged animals (one wild boar and one domestic pig) at 4 days postinfection (d.p.i.) (15) . The MFI values for the four samples ranged from 4,498 to 5,367. In addition, one sample, which was taken from a challenged pig at 10 d.p.i., tested positive by the immunoassay but negative by the commercial CSFV E2 ELISA kit.
CSFV E rns antibody detection was evaluated with 187 samples that had been tested by a test version of the PrioCHECK CSFV E rns ELISA, which was the only kit available then but needed further optimization and thorough validation. The ELISA results were used as arbitrary references for preliminary comparison with the Luminex assay. Under the cutoff value of Ͼ4,070.75, as suggested by ROC analysis, 155 out of the 187 samples showed the same results by the microsphere immunoassay and by ELISA. The samples with different results are listed in Table S1 in the supplemental material. While 15 samples were found E rns antibody negative by the immunoassay but positive by ELISA, 17 samples were regarded E rns antibody positive by the immunoassay but negative by ELISA. It has to be noted that 13 out of the 15 immunoassaynegative samples were taken within 10 days after infection/vaccination, when the E rns antibodies were likely present in a very low titer, and that 14 out of the 17 immunoassay-positive samples were taken at least 14 days after vaccination/infection when specific IgG usually develops upon infection/vaccination. Given the unsatisfactory performance of the CSFV E rns ELISA, the immunoassay seemed to have improved sensitivity and specificity for CSFV E rns antibody detection compared to those of the ELISA. All 80 serum samples from a naive pig population in Sweden tested negative by the immunoassay, with a median MFI value of 269. Five out of the 66 CSF reference serum samples were scored E rns antibody negative by the immunoassay, with MFI values ranging from 537 to 2,018. Because the PrioCHECK CSFV E rns ELISA was a prototype version and not a fully validated kit, specificity and sensitivity values were not calculated, as they would not have accurately reflected the full capability of the assay.
Detection of BVDV E rns antibodies upon vaccination. The multiplex microsphere immunoassay detected antibodies against BVDV E rns in the vaccinated pig population. Thirty-four pigs were vaccinated with the CP7_E2alf marker vaccine candidate and sampled 3 weeks postvaccination and up to 6 months postvaccination (15, 18 ). The samples were tested by the multiplex immunoassay for the detection of BVDV E rns antibodies. The MFI values ranged from 608 to 11, 190 , with a median value of 1,403. The 95% confidence interval for the median MFI was 1,096 to 2,152. When the 80 negative Swedish serum samples were tested, the MFI values for BVDV E rns antibody detection were between 27 and 6,720, with a median value of 762. The 95% confidence interval for the median was 664 to 912. As the MFI values from vaccinated pigs were slightly higher than those from naive pigs, a very low-level antibody response to BVDV E rns antigen in pigs upon vaccination with CP7_E2alf was suggested. The antibody response was consistently observed regardless of the sampling time points (1, 3, and 6 months postvaccination) or the vaccination route (oral or intramuscular). The low-level and slow development of BVDV E rns antibodies was in sharp contrast to the rapid development of CSFV E2 antibodies to high titers.
DIVA potential of the multiplex microsphere immunoassay. To evaluate the potential to differentiate wild-type CSFV infection from marker vaccination, the 356 samples tested were grouped into one of four populations: naive (Swedish swine sera; n ϭ 80); wild-type CSFV infected (n ϭ 96), including CSF reference sera, German CSFV batch and part of vaccination/challenge; marker vaccinated (n ϭ 34); and vaccinated and subsequently infected (n ϭ 146). The marker-vaccinated and the vaccinated-and-subsequently-infected groups were from the vaccination/challenge. The results are presented as a box-and-whisker plot in Fig. 2 , and the median MFI values and 95% confidence intervals are listed in Table 3 .
The naive population was negative for CSFV E2 and E rns antibodies and had slightly higher MFI values for BVDV E rns antibody. In the infected group, CSFV E2 antibodies were positive in all samples with high MFI values, whereas CSFV E rns antibodies were positive in 89 out of 96 samples. The negative samples included three reference samples against the live attenuated Riems strain, which induced a late or low E rns antibody response upon vaccination. Cross-reactivity of the BVDV E rns antigen with CSFV E rns antibodies was observed. In the vaccinated population, except for two samples, the MFI values for the CSFV E2 antibodies were high above the cutoff values, while the CSFV E rns antibodies remained negative. The MFI values for the BVDV E rns antibodies were similar to those found in the naive population. Finally, in the more complicated vaccination/challenge group, while the CSFV E rns MFI values were similar to those in the infected group, the CSFV E2 MFI values were the highest among all groups. Two samples were E2 antibody negative, and three positive outliers had relatively low MFI values (6,300 to 16,000). The two negative sera were sampled at 4 days p.i. However, when sampled at 7 days p.i., both became strongly positive, with MFI values of Ͼ23,000. The three outliers with low MFI values were also sampled at 4 days p.i. and reached high MFI values within 3 days.
DISCUSSION
Marker vaccines, such as CP7_E2alf, have to be accompanied by reliable discriminatory assays. However, currently available approaches have shown drawbacks in either sensitivity/specificity or large-scale application (e.g., the detection of the CSFV E rns antibodies by ELISA is problematic, which is likely due to the crossreactivity with antibodies against BVDV or BDV). Within the framework of the EU project "CSFV_goDIVA," two CSFV E rnsbased ELISAs were developed using viral antigens produced in E. coli and evaluated for the detection and differentiation of infected from vaccinated animals and for further discrimination of pestivirus antibodies (22) . The current study took a different approach; the three viral proteins were produced in insect cells using a baculovirus expression system (aiming for a better posttranslational modification of the proteins) and used as antigens in a microsphere immunoassay. Unlike the ELISA, in the Luminex assay, antigens are coupled to suspension microspheres, which allows a high degree of multiplexing capacity by mixing sets of microspheres coupled with different antigens. For example, a 30-plex Luminex panel is commercially available for the detection and quantification of human cytokines, chemokines, and growth factors in serum, plasma, and tissue culture supernatant in less than 1 day (Life Technologies), which would be difficult to achieve by ELISA. Conversely, it takes more effort and time, and it is always a great challenge to develop and validate such a multiplex microsphere immunoassay.
It has been reported that CSFV E2 produced using a baculovirus system results in higher sensitivities and specificities when evaluated in different ELISA formats (23) . In this study, none of the viral proteins was fully glycosylated, which may be a reason for the lower sensitivity of E rns antibody detection. While BVDV E rns had slightly higher background binding and cross-reacted with CSFV E rns antibodies, the CSFV E2 and E rns antigens reacted specifically to the respective antibodies. In addition, the immunoassay has improved CSFV E rns antibody detection (compared to that of the ELISA), which is likely due to better binding between the antibody and antigen. Nevertheless, the multiplex immunoassay can be readily used as an alternative method for the diagnosis of CSF.
Following vaccination with CP7_E2alf, the BVDV E rns antibody response was surprisingly weak. With the exchange of the CSFV E2 gene, the tissue tropism of the BVDV-backboned chimeric vaccine candidate has been changed and the virus has a very limited replication in pigs (6), which is barely detectable by a highly sensitive real-time reverse transcriptase PCR (RT-PCR) (15) . Compared to the potent E2 protein, the BVDV E rns protein induced a weak immune response in pigs vaccinated with the marker vaccine candidate CP7_E2alf. In most cases, the BVDV E rns MFI values from the vaccinated pigs were similar to those found in naive pigs, while the E2 MFI values were much higher than the values obtained from naive pigs. It has been demonstrated that the BVDV E rns can induce a rapid immune response in calves within 2 weeks of postexperimental infection with BVDV-1 or atypical bovine pestivirus, and the MFI values increased up to 20,000 (cutoff value, 2,800) (24) . The chimeric nature of the marker vaccine candidate CP7_E2alf may be the reason for the observed difference of the BVDV E rns protein in inducing immune responses in pigs vaccinated with CP7_E2alf and in calves infected with wild-type BVDV.
The focus of this study was on the DIVA potential of the multiplex microsphere immunoassay, which is an essential component of the marker vaccine concept and DIVA diagnostics. In the naive pig population, the antibodies against all three viral proteins were regarded negative. In the infected group, where the CSFV E2 and E rns antibodies should theoretically be positive, all 96 serum samples tested positive for the E2 antibody, and 89 out of 96 samples were positive for the CSFV E rns antibody by the multiplex immunoassay. The seven E rns antibody-negative samples were from four pigs infected with the Riems strain and from three pigs that had a low neutralization peroxidase-linked assay (NPLA) titer of 60 using the CSFV Alfort strain. Cross-reactivity of the BVDV E rns antigen with CSFV E rns antibodies was observed in this group, which was also reported recently (17, 25) . In contrast, the CSFV E rns antibodies remained negative in the vaccinated group, and E2 antibodies were all positive except two samples that had NPLA titers of 20 and 160. The distinct feature of CSFV E rns antibody detection in the two groups confirmed the DIVA potential of the multiplex microsphere immunoassay.
It is also possible that the vaccinated pigs or wild boar are infected with wild-type viruses in the field. As the BVDV E rns protein present in the marker vaccine induced a very weak immune response and cross-reacted with the CSFV E rns antibody, the detection of BVDV E rns antibody was unreliable for distinguishing the infected group from the vaccination/challenge group. However, E2 antibody detection in the vaccination/challenge group had a characteristic phenomenon (high median MFI values with short ranges), which was also observed in another study where ELISA was used to detect E2 antibodies (18) . As this characteristic profile of E2 antibody detection was observed in neither the infected group nor the vaccinated group, it can be a strong indication of the vaccination and subsequent infection status. Importantly, the detection of CSFV E rns antibody in a population indicates wild-type infection that will surely require more thorough investigations.
In conclusion, the recombinant CSFV E2, CSFV E rns , and BVDV CP7 E rns proteins were produced using a baculovirus expression system and used for developing a multiplex microsphere immunoassay. The assay detected and differentiated antibodies raised against wild-type CSFV infection and vaccination with CP7_E2alf. It also revealed an unexpectedly slow development of BVDV E rns antibody in the vaccinated pigs. This microsphere immunoassay provides a platform to multiplex additional antigens for the simultaneous detection and differentiation of different porcine pathogens.
